In the single-arm phase IV Re:Mission trial, 4/4 patients with FLT3-ITD+ AML relapsed within 200 days,18 suggesting that the anti-leukemic efficacy of HDC/IL-2 among normal karyotype patients instead may derive from NPM1-mutated AML. The gene discussed is IL2; the disease is acute myeloid leukemia.